Lineage Cell Therapeutics (LCTX) Cash & Current Investments (2010 - 2026)

Lineage Cell Therapeutics has reported Cash & Current Investments for 17 years, with the latest figure at $62.7 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments rose 30.92% year-over-year to $62.7 million; the trailing twelve-month figure through Mar 2026 stood at $62.7 million (up 30.92% YoY), and the FY2025 full-year result was $61.0 million, up 41.64% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $62.7 million, up from $61.0 million in the prior quarter.
• The five-year high for Cash & Current Investments was $79.9 million in Q1 2022, with the low at $32.2 million in Q3 2025.
• Historically, Cash & Current Investments has averaged $49.6 million across 5 years, with a median of $45.9 million in 2023.
• Annual changes were most pronounced in 2023 — Cash & Current Investments slumped 41.44% — and 2025, when it soared 41.64%.
• Lineage Cell Therapeutics' Cash & Current Investments stood at $57.9 million in 2022, then tumbled by 38.67% to $35.5 million in 2023, then climbed by 21.25% to $43.0 million in 2024, then surged by 41.64% to $61.0 million in 2025, then advanced by 2.89% to $62.7 million in 2026.
• The last three Cash & Current Investments figures came in at $62.7 million (Q1 2026), $61.0 million (Q4 2025), and $32.2 million (Q3 2025), per Business Quant data.